{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bacterial+Disease&page=4",
    "query": {
      "condition": "Bacterial Disease",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 2406,
    "total_pages": 241,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bacterial+Disease&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bacterial+Disease&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T03:43:50.088Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02735707",
      "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Tract Diseases",
        "Influenza (Pandemic)",
        "Influenza",
        "Community Acquired Pneumonia",
        "Community Acquired Pneumonia (CAP)",
        "Community Acquired Pneumonia, Severe",
        "COVID-19",
        "Respiratory Tract Infection Acute",
        "Respiratory Tract Infections (RTI)",
        "SARS CoV 2 Infection"
      ],
      "interventions": [
        {
          "name": "Ceftriaxone + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin or Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-tazobactam + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Ceftaroline + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin-clavulanate + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Standard course macrolide",
          "type": "DRUG"
        },
        {
          "name": "Extended course macrolide",
          "type": "DRUG"
        },
        {
          "name": "No systemic corticosteroid",
          "type": "OTHER"
        },
        {
          "name": "Fixed-duration Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Shock-dependent hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration higher dose Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for influenza",
          "type": "OTHER"
        },
        {
          "name": "Five-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Lopinavir / Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine + lopinavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Ivermectin",
          "type": "DRUG"
        },
        {
          "name": "No immune modulation for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Local standard venous thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "Conventional low dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Continuation of therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "No immunoglobulin",
          "type": "OTHER"
        },
        {
          "name": "Convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Delayed administration of convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "No vitamin C",
          "type": "OTHER"
        },
        {
          "name": "Vitamin C",
          "type": "DRUG"
        },
        {
          "name": "No antiplatelet",
          "type": "OTHER"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "P2Y12 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "No simvastatin",
          "type": "OTHER"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Eritoran",
          "type": "DRUG"
        },
        {
          "name": "Apremilast",
          "type": "DRUG"
        },
        {
          "name": "Clinician-preferred mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "Protocolised mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "No renin-angiotensin system inhibitor",
          "type": "OTHER"
        },
        {
          "name": "Angiotensin converting enzyme inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin Receptor Blockers",
          "type": "DRUG"
        },
        {
          "name": "ARB + DMX-200",
          "type": "DRUG"
        },
        {
          "name": "No cysteamine",
          "type": "OTHER"
        },
        {
          "name": "Cysteamine",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Baloxavir Marboxil",
          "type": "DRUG"
        },
        {
          "name": "Five-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "No endothelial modulator",
          "type": "OTHER"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        },
        {
          "name": "No Immune Modulator for Influenza",
          "type": "OTHER"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir + remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin-clavulanate + Ceftazidime + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Meropenem + Macrolide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "UMC Utrecht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "28 Days and older"
      },
      "enrollment_count": 20000,
      "start_date": "2016-04-11",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 11,
      "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735707"
    },
    {
      "nct_id": "NCT01352793",
      "title": "A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis, Meningococcal"
      ],
      "interventions": [
        {
          "name": "rLP2086 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 5715,
      "start_date": "2012-11",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-03-11",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 39,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01352793"
    },
    {
      "nct_id": "NCT01790893",
      "title": "Treatment for Presumed Ocular Histoplasmosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ocular Histoplasmosis"
      ],
      "interventions": [
        {
          "name": "aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Kitchens, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2013-03",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 3,
      "location_summary": "Augusta, Georgia • Lexington, Kentucky • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01790893"
    },
    {
      "nct_id": "NCT06212999",
      "title": "A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hidradenitis Suppurativa (HS)"
      ],
      "interventions": [
        {
          "name": "Povorcitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 617,
      "start_date": "2024-01-30",
      "completion_date": "2026-12-26",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 61,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Laguna Niguel",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06212999"
    },
    {
      "nct_id": "NCT01049035",
      "title": "A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meningitis",
        "Meningococcal Infection"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "365 Days",
        "sex": "ALL",
        "summary": "42 Days to 365 Days"
      },
      "enrollment_count": 580,
      "start_date": "2009-12-16",
      "completion_date": "2012-02-13",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01049035"
    },
    {
      "nct_id": "NCT01379040",
      "title": "Volatile Organic Compounds in Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis",
        "Pseudomonas Aeruginosa"
      ],
      "interventions": [
        {
          "name": "Cystic Fibrosis patients",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Landon Pediatric Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "1 Year to 40 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-08",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2014-08-13",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01379040"
    },
    {
      "nct_id": "NCT05794191",
      "title": "A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Pneumonia",
        "Infections, Pneumococcal"
      ],
      "interventions": [
        {
          "name": "Vaccine Administration",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350399,
      "start_date": "2023-03-22",
      "completion_date": "2024-08-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05794191"
    },
    {
      "nct_id": "NCT02557685",
      "title": "Gut Microbiota Changes After Fecal Microbiota Transplantation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile Infection"
      ],
      "interventions": [
        {
          "name": "Fecal Microbiota Transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The Miriam Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-06",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2015-09-23",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02557685"
    },
    {
      "nct_id": "NCT03572049",
      "title": "Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Invasive Fungal Infections"
      ],
      "interventions": [
        {
          "name": "SUBA itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Conventional itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2018-09-17",
      "completion_date": "2022-04-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03572049"
    },
    {
      "nct_id": "NCT00326443",
      "title": "CVD 909 Vi Prime Boost Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Typhoid Fever"
      ],
      "interventions": [
        {
          "name": "CVD 909",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Vi Polysaccharide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 21,
      "start_date": "2006-02",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-11-19T03:43:50.088Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326443"
    }
  ]
}